Ketryx raises $39 million in Series B funding to expand AI compliance tools for life sciences
Table of Contents
Cambridge, Massachusetts–based Ketryx, a software platform company that automates regulatory compliance for medical device and life sciences companies, has secured $39 million in Series B funding led by Transformation Capital, pushing its total raised to more than $55 million. The investment comes as the industry grapples with integrating AI into products amid tightening FDA rules, including the Quality Management System Regulation set to take effect in February 2026. Ketryx, claims its tools cut documentation time by up to 90% and speed release cycles by 10 times, with adoption by three of the top five global medtech firms and companies like DeepHealth, HeartFlow, Beacon Biosignals and Aignostics. CEO Erez Kaminski said the funds will fuel global expansion and product development. Transformation Capital partner Vinay Shah joins the board.
